|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1201 Maryland Avenue SW |
Address2 | Suite 900 |
| City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 6245-12
|
||||||||
|
6. House ID# 325050000
|
||||||||
| TYPE OF REPORT | 8. Year | 2008 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Brent DelMonte, Vice President for Federal Government Relations |
Date | 10/20/2008 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ACC
16. Specific lobbying issues
Sarbanes-Oxley Reform
Section 404
S.3260: Financial Services and General Government Appropriations Act for FY 2009
Election of R&D/AMT Tax Credits in Lieu of Bonus Depreciation
H.R. 3221
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Treasury - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
|
Alan |
Eisenberg |
|
|
|
Eli |
Joseph |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Tooshar |
Swain |
|
Legislative Correspondent, Senator Rick Santorum |
|
Paul |
Poteet |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
U.S. Policy on Sustainable Agriculture Standard
American National Standards Institute (ANSI)
Livestock Cloning/Product Labeling
FDA Risk Assessment on Cloning
USDA Marketing and Regulatory Programs, Cloning Transition Period
USDA Economic Report on Impact of Cloning on US Agriculture and Food Production
USDA National Organic Program, Advance Notice of Proposed Rulemaking
S: 3289: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY
2009
H.R. 6432
Foreign Agricultural Biotechnology Laws and Regulations
U.S. Korea Free Trade Agreement
China Biotechnology Trade Negotiations
Mexico Biotechnology Trade Negotiations
Vietnam Biotechnology Negotiations
France Trade Meetings
Taiwan Biotechnology Negotiations
EU Trade Negotiations
Korea Biotechnology Trade Negotiations
Canada Biotechnology Trade Negotiations
Japan Biotechnology Trade Negotiations
Peru Biotechnology Trade Negotiations
Argentina Biotechnology Trade negotiations
Adventitious Presence (Low Level Presence)
U.S. Government Policy Position for Codex Guidelines on Adventitious Presence
European Union Low Level Presence Policy
World Trade Organization on EU Biotech Approvals
Review of EU Biotechnology Negotiations
Genetically Engineered (GE) Animals
U.S. Government Policy Position for Codex Guidelines on Food Safety Risk Assessment for rDNA Animals
FDA and USDA Draft Regulation of GE Animals
Biotechnology Crop Stewardship
Biotechnology Quality Management Stewardship
Cartagena Biosafety Protocol
U.S. Government Positions/Activities/Communications at Biosafety Protocol Meetings
USDA/APHIS Agricultural Biotechnology Regulations
USDA Rulemaking on 7 CFR 340
EU Tracebility and Labeling Regulations for Ag-Biotech
U.S. Policy on Ag-Biotech Benefits for G-8 Meeting
Policies Impacting Global Trade of Ag-Biotech Products
U.S. Government Positions
Funding for the USDA
S:3289: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY
2009
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Agriculture - Dept of (USDA), U.S. Trade Representative (USTR), Commerce - Dept of (DOC), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), State - Dept of (DOS), White House Office, Environmental Protection Agency (EPA), U.S. Agency for International Development (USAID), Office of Management & Budget (OMB),
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Bill |
Olson |
|
Legislative Assistant, Rep. John Shimkus |
|
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
|
Sharon |
Bomer Lauritsen |
|
|
|
Barbara |
Glenn |
|
|
|
Sarah |
Lukie |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Genetically Engineered (GE) Animals
U.S. Government Policy Position for Codex Guidelines on Food Safety Risk Assessment for rDNA Animals
FDA and USDA Draft Regulation of GE Animals
Livestock Cloning/Product Labeling
FDA Risk Assessment on Cloning
USDA Marketing and Regulatory Programs, Cloning Transition Period
USDA Economic Report on Impact of Cloning on US Agriculture and Food Production
USDA National Organic Program, Advance Notice of Proposed Rulemaking
S: 3289: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY
2009
H.R. 6432
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Agriculture - Dept of (USDA), Commerce - Dept of (DOC), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Office of Science & Technology Policy (OSTP), State - Dept of (DOS), White House Office, U.S. Trade Representative (USTR), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Barbara |
Glenn |
|
|
|
Sharon |
Bomer Lauritsen |
|
|
|
Bill |
Olson |
|
Legislative Assistant, Rep. John Shimkus |
|
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
|
Melissa |
Bowie |
|
Chief Health Counsel, Senate HELP, Subcommittee |
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
S: 3289: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY 2009
Funding for the Food and Drug Administration (Human Drug, Biologics, Food Safety, Critical Path, Regan-Udall Foundation,
Center for Veterinary Medicine)
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY 2009 (Cont...)
Funding for the USDA (Office of General Counsel, Biotechnology Regulatory Service (APHIS), Animal Care &
Veterinary Services (APHIS), Trade Activities (Office of the Secretary & Food Safety Inspection Service), Agriculture
Research Service, Biofuels (Rural Development))
Drug Importation
Livestock Cloning/Product Labeling
S: 3230: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY
2009
Funding for National Institutes of Health
Funding for Bioterrorism and Emergency Preparedness
Funding for Pandemic Influenza Preparedness
Funding for Biomedical Advanced Research & Development Authority (BARDA)
Drug Importation
S: 3258: Energy and Water Development and Related Agencies Appropriations Act for FY 2009
Funding for Biofuels
S.3260: Financial Services and General Government Appropriations Act for FY 2009
Sarbanes Oxley - Section 404
S: 3282: Commerce, Justice, Science, and Related Agencies Appropriations Act for FY 2009
Funding for Technology Innovation Program (TIP)
Department of State, Foreign Operations and Related Programs Appropriations Act for FY 2009
Funding for Biotechnology Research and Development Programs at the Agency for International Development
H.R. 2638: Consolidated Security, Disaster Assistance, and Continuing Appropriations Act for FY 2009
Funding for National Institutes of Health
Funding for Bioterrorism and Emergency Preparedness
Funding for Pandemic Influenza Preparedness
Funding for the Food and Drug Administration
H.R. 7110/S.3604: Second Supplemental Appropriations Act
Funding for National Institutes of Health
Funding for Bioterrorism and Emergency Preparedness
Funding for Pandemic Influenza Preparedness
Funding for the Food and Drug Administration
Department of Homeland Security Appropriations Act for FY 2009
Drug Importation
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
|
Sara |
Radcliffe |
|
|
|
John |
Taylor |
|
|
|
Melissa |
Bowie |
|
Chief Health Counsel, Senate HELP, Subcommittee |
|
Daryl |
Pritchard |
|
|
|
Andrew |
Emmett |
|
|
|
Eli |
Joseph |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Patent Reform
H.R. 1908
S. 1145
S.3600
PTO Reform
CBD TRIPS Amendment
Patent Disclosure Requirements
Intellectual Property and Access to Medicines for Neglected Diseases and Diseases of Developing World
U.S. Government Positions in WTO, WHO Negotiations
Bayh-Dole Act Evaluation
Intellectual Property Enforcement
S.3464
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Patent & Trademark Office (PTO), U.S. Trade Representative (USTR), State - Dept of (DOS), Commerce - Dept of (DOC), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lila |
Feisee |
|
|
|
Tom |
DiLenge |
|
|
|
Hansjorg |
Sauer |
|
|
|
John |
Taylor |
|
|
|
Melissa |
Bowie |
|
Chief Health Counsel, Senate HELP, Subcommittee |
|
Eli |
Joseph |
|
|
|
Paul |
Poteet |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
Genetically Engineered (GE) Animals
U.S. Government Policy Position for Codex Guidelines on Food Safety Risk Assessment for rDNA Animals
FDA and USDA Draft Regulation of GE Animals
Drug Safety
Implementation of Food & Drug Administration Amendments Act of 2007
Clinical Trial Registry and Results Databases
Risk Management Plans
Heparin Contamination
H.R. 5839: Safeguarding America's Pharmaceuticals Act of 2008
FDA Globalization Act of 2008
H.R. 3610: The Food and Drug Import Safety Act of 2007
S.3409: Safeguarding America's Pharmaceuticals Act of 2008
Drug Importation
S: 3230: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY
2009
S. 3181: Department of Homeland Security Appropriations Act for FY 2009
S: 3289: Departments of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies
Appropriations Act for FY 2009
Adventitious Presence (Low Level Presence)
U.S. Government Policy Position for Codex Guidelines on Adventitious Presence
European Union Low Level Presence
Physician Payments Sunshine Act
S.2029
Livestock Cloning/Product Labeling
FDA Risk Assessment on Cloning
USDA Marketing and Regulatory Programs, Cloning Transition Period
USDA Economic Report on Impact of Cloning on US Agriculture and Food Production
USDA National Organic Program, Advance Notice of Proposed Rulemaking
S: 3289: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY
2009
H.R. 6432
Access to Drug Pricing Data
H.R. 5683
Funding for Food Safety at the Food and Drug Administration
S: 3289: Departments of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies
Appropriations Act for FY 2009
H.R. 2638: Consolidated Security, Disaster Assistance, and Continuing Appropriations Act for FY 2009
H.R. 7110/S.3604: Second Supplemental Appropriations Act for FY 2008
Human Subject Protections in Clinical Trials
Human Growth Hormone Regulation
S.877
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Agriculture - Dept of (USDA), Commerce - Dept of (DOC), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Office of Science & Technology Policy (OSTP), State - Dept of (DOS), U.S. Trade Representative (USTR), White House Office, Natl Institutes of Health (NIH), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sara |
Radcliffe |
|
|
|
John |
Taylor |
|
|
|
Sharon |
Bomer Lauritsen |
|
|
|
Barbara |
Glenn |
|
|
|
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
|
Bill |
Olson |
|
Legislative Assistant, Rep. John Shimkus |
|
Jeanne |
Haggerty |
|
Policy Advisor, Congressman Joe Barton |
|
Melissa |
Bowie |
|
Chief Health Counsel, Senate, HELP Subcommittee |
|
Eli |
Joseph |
|
|
|
Sandra |
Dennis |
|
|
|
Tom |
DiLenge |
|
|
|
Andrew |
Emmett |
|
|
|
Katherine |
Sawyer |
|
|
|
Laurel |
Todd |
|
|
|
Lauren |
Neff |
|
Leg. Assistant, Congresswoman Deborah Pyrce |
|
Sarah |
Lukie |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
Biofuels Tax Credit
Funding for Biofuels
S:3258: Energy and Water Development and Related Agencies Appropriations Act for FY 2009
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Treasury - Dept of,
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brent |
Erickson |
|
|
|
Matt |
Carr |
|
|
|
Amy |
Ehlers |
|
|
|
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
|
Paul |
Poteet |
|
|
|
Brent |
DelMonte |
|
|
|
Eli |
Joseph |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Adventitious Presence (Low Level Presence)
U.S. Government Policy Position for Codex Guidelines on Adventitious Presence
European Union Low Level Presence Policy
Genetically Engineered (GE) Animals
U.S. Government Policy Position for Codex Guidelines on Food Safety Risk Assessment for rDNA Animals
FDA and USDA Draft Regulation of GE Animals
Livestock Cloning/Product Labeling
FDA Risk Assessment on Cloning
USDA Marketing and Regulatory Programs, Cloning Transition Period
USDA Economic Report on Impact of Cloning on US Agriculture and Food Production
USDA National Organic Program, Advance Notice of Proposed Rulemaking
S: 3289: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY
2009
H.R. 6432
Funding for Food Safety at the Food and Drug Administration
S: 3289: Departments of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies
Appropriations Act for FY 2009
H.R. 2638: Consolidated Security, Disaster Assistance, and Continuing Appropriations Act for FY 2009
H.R. 7110/S.3604: Second Supplemental Appropriations Act for FY 2008
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Agriculture - Dept of (USDA), Commerce - Dept of (DOC), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), State - Dept of (DOS), U.S. Trade Representative (USTR), White House Office, Office of Science & Technology Policy (OSTP), Office of Management & Budget (OMB), U.S. Agency for International Development (USAID), Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sharon |
Bomer Lauritsen |
|
|
|
Barbara |
Glenn |
|
|
|
Bill |
Olson |
|
Legislative Assistant, Rep. John Shimkus |
|
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
|
Melissa |
Bowie |
|
Chief Health Counsel, Senate HELP Subcommitte |
|
Eli |
Joseph |
|
|
|
John |
Taylor |
|
|
|
Sara |
Radcliffe |
|
|
|
Sarah |
Lukie |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FUE
16. Specific lobbying issues
Biofuels Tax Credit
Renewable Fuels Standard
Funding for Biofuels
S.3258: Energy and Water Development and Related Agencies Appropriations Act for FY 2009
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Energy - Dept of, Agriculture - Dept of (USDA), Office of Management & Budget (OMB), Treasury - Dept of, Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matt |
Carr |
|
|
|
Amy |
Ehlers |
|
|
|
Brent |
Erickson |
|
|
|
Bill |
Olson |
|
Legislative Assistant, Rep. John Shimkus |
|
Brent |
DelMonte |
|
|
|
Paul |
Poteet |
|
|
|
Eli |
Joseph |
|
|
|
Patrick |
Carroll |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Drug Safety
Implementation of Food & Drug Administration Amendments Act of 2007
Clinical Trial Registry and Results Databases
Risk Management Plans
Drug Safety Cont...
Heparin Contamination
FDA Globalization Act of 2008
H.R. 5839 Safeguarding America's Pharmaceuticals Act of 2008
H.R. 3610: The Food and Drug Import Safety Act of 2007
S.3409: Safeguarding America's Pharmaceuticals Act of 2008
Stem Cell Research
Medicaid Rebates
H.R. 1424
H.R. 1367
S.3101
Medicaid/Medicare Packages
Dual Proportionality
Medicaid Rebates in Hospital Outpatient Setting
CMS AMP Regulations
Human Growth Hormone Regulation
S.877
Follow-on Biologics
H.R. 1038
H.R. 1956
H.R. 5629
S. 1695
FDA Regulatory Processes for First-Time Filers
Funding for Biomedical Advanced Research & Development Authority (BARDA)
S: 3230: Departments of Labor, Health and Human Services and Education, and Related Agencies Appropriations
Act for FY 2009
Vaccine Financing
National Vaccine Advisory Committee Draft Recommendations
Barriers and Incentives Related to Personalized Medicine
Outpatient Prospective Payment System
S. 3101: Medicare Improvements for Patients and Providers Act of 2008
CMS ASP + 4% Proposed Regulation
In Vitro Diagnostics
Regulatory Oversight
Comparative Effectiveness Program Initiatives
H.R. 6331
S. 3101
S.3408
Medicare/Medicaid Packages
Human Subject Protections in Clinical Trials
International Market Access for U.S. Healthcare Products
Alliance for Healthcare Competitiveness
Funding for National Institutes of Health
S. 3230: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY
2009
H.R. 2638: Consolidated Security, Disaster Assistance, and Continuing Appropriations Act for 2009
H.R. 7110/S.3604: Second Supplemental Appropriations Act for FY 2008
Funding for Bioterrorism and Emergency Preparedness
S. 3230: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY
2009
H.R. 2638: Consolidated Security, Disaster Assistance, and Continuing Appropriations Act for 2009
H.R. 7110/S.3604: Second Supplemental Appropriations Act for FY 2008
Funding for Pandemic Influenza Preparedness
S. 3230: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY
2009
H.R. 2638: Consolidated Security, Disaster Assistance, and Continuing Appropriations Act for 2009
H.R. 7110/S.3604: Second Supplemental Appropriations Act for FY 2008
Funding for the Food and Drug Administration
S. 3230: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY
2009
H.R. 2638: Consolidated Security, Disaster Assistance, and Continuing Appropriations Act for 2009
H.R. 7110/S.3604: Second Supplemental Appropriations Act for FY 2008
Physician Payments Sunshine Act
S.2029
Access to Drug Pricing Data
H.R. 5683
Drug Importation
S.3230: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY
2009
Department of Homeland Security Appropriations Act for FY 2009
S. 3289: Departments of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies
Appropriations Act for FY 2009
Intellectual Property and Access to Medicines for Neglected Diseases and Diseases of Developing World
U.S. Government Positions in WTO, WHO Negotiations
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Centers For Medicare and Medicaid Services (CMS), Natl Institutes of Health (NIH), U.S. Trade Representative (USTR), Commerce - Dept of (DOC), Patent & Trademark Office (PTO)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Taylor |
|
|
|
Sara |
Radcliffe |
|
|
|
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
|
Tricia |
Brooks |
|
|
|
Melissa |
Bowie |
|
Chief Health Counsel, Senate HELP, Subcommittee |
|
Jeanne |
Haggerty |
|
Policy Advisor, Congressman Joe Barton |
|
Eli |
Joseph |
|
|
|
Sandra |
Dennis |
|
|
|
Edward |
Buckley |
|
|
|
Paul |
Poteet |
|
|
|
Daryl |
Pritchard |
|
|
|
Katherine |
McCarthy |
|
|
|
Hansorg |
Sauer |
|
|
|
Tom |
DiLenge |
|
|
|
Lila |
Feisee |
|
|
|
Lauren |
Neff |
|
Leg., Asst., Congresswoman Deborah Pryce |
|
Laurel |
Todd |
|
|
|
Brent |
DelMonte |
|
|
|
Cartier |
Esham |
|
|
|
Andrew |
Emmett |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Funding for Biomedical Advanced Research Development Authority (BARDA)
S: 3230: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2009
Funding for Bioterrorism and Emergency Preparedness
S. 3230: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY
2009
H.R. 2638: Consolidated Security, Disaster Assistance, and Continuing Appropriations Act for 2009
H.R. 7110/S.3604: Second Supplemental Appropriations Act for FY 2008
Funding for Pandemic Influenza Preparedness
S. 3230: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY
2009
H.R. 2638: Consolidated Security, Disaster Assistance, and Continuing Appropriations Act for 2009
H.R. 7110/S.3604: Second Supplemental Appropriations Act for FY 2008
17. House(s) of Congress and Federal agencies Check if None
Health & Human Services - Dept of (HHS), U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
|
Melissa |
Bowie |
|
Chief Health Counsel, Senate HELP, Subcommittee |
|
John |
Taylor |
|
|
|
Sara |
Radcliffe |
|
|
|
Eli |
Joseph |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Funding for Biomedical Advanced Research Development Authority (BARDA)
S: 3230: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2009
Funding for National Institutes of Health
S. 3230: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY
2009
H.R. 2638: Consolidated Security, Disaster Assistance, and Continuing Appropriations Act for 2009
H.R. 7110/S.3604: Second Supplemental Appropriations Act for FY 2008
Funding for the Food and Drug Administration
S. 3230: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY
2009
H.R. 2638: Consolidated Security, Disaster Assistance, and Continuing Appropriations Act for 2009
H.R. 7110/S.3604: Second Supplemental Appropriations Act for FY 2008
Funding for Bioterrorism and Emergency Preparedness
S. 3230: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY
2009
H.R. 2638: Consolidated Security, Disaster Assistance, and Continuing Appropriations Act for 2009
H.R. 7110/S.3604: Second Supplemental Appropriations Act for FY 2008
Funding for Pandemic Influenza Preparedness
S. 3230: Departments of Labor, health and Human Services, and Education, and Related Agencies Appropriations Act for FY
2009
H.R. 2638: Consolidated Security, Disaster Assistance, and Continuing Appropriations Act for 2009
H.R. 7110/S.3604: Second Supplemental Appropriations Act for FY 2008
In Vitro Diagnostics
Regulatory Oversight
Comparative Effectiveness Program Initiatives
H.R. 6331
S. 3101
S.3408
Medicare/Medicaid Packages
Stem Cell Research
Human Subject Protections in Clinical Trials
Barriers and Incentives Related to Personalized Medicine
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Eli |
Joseph |
|
|
|
Melissa |
Bowie |
|
Chief Health Counsel, Senate HELP, Subcommittee |
|
Sara |
Radcliffe |
|
|
|
John |
Taylor |
|
|
|
Daryl |
Pritchard |
|
|
|
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
|
Sandra |
Dennis |
|
|
|
Katherine |
Sawyer |
|
|
|
Jeanne |
Haggerty |
|
Policy Advisor, Congressman Joe Barton |
|
Edward |
Buckley |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Outpatient Prospective Payment System
S. 3101: Medicare Improvements for Patients and Providers Act of 2008
CMS ASP+ 4% Proposed Regulation
Medicaid Rebates
H.R. 1424
H.R. 6331
S.3101
Medicaid/Medicare Packages
Dual Proportionality
Medicaid Rebates in Hospital Outpatient Setting
CMS AMP Regulations
Access to Drug Pricing Data
H.R. 5683
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Taylor |
|
|
|
Jeanne |
Haggerty |
|
Policy Advisor, Congressman Joe Barton |
|
Sandra |
Dennis |
|
|
|
Eli |
Joseph |
|
|
|
Laurel |
Todd |
|
|
|
Lauren |
Neff |
|
Leg. Asst., Congresswoman Deborah Pryce |
|
Melissa |
Bowie |
|
Chief Health Counsel, Senate HELP, Subcommittee |
|
Tom |
DiLenge |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Access to Drug Pricing Data
H.R. 5683
Comparative Effectiveness Program Initiatives
H.R. 6331
S. 3101
S.3408
Medicare/Medicaid Packages
Medicaid Rebates
H.R. 1424
H.R. 6331
S.3101
Medicaid/Medicare Packages
Dual Proportionality
Medicaid Rebates in Hospital Outpatient Setting
CMS AMP Regulations
Outpatient Prospective Payment System
S. 3101: Medicare Improvements for Patients and Providers Act of 2008
CMS ASP+ 4% Proposed Regulation
Drug Safety
Implementation of Food & Drug Administration Amendments Act of 2007
Clinical Trial Registry and Results Databases
Risk Management Plans
Heparin Contamination
H.R. 5839: Safeguarding America's Pharmaceuticals Act of 2008
FDA Globalization Act of 2008
H.R. 3610: The Food and Drug Import Safety Act of 2007
S.3409: Safeguarding America's Pharmaceuticals Act of 2008
Drug Importation
S: 3230: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY
2009
S. 3181: Department of Homeland Security Appropriations Act for FY 2009
S: 3289: Departments of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies
Appropriations Act for FY 2009
Funding for the Food and Drug Administration
S. 3230: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY
2009
H.R. 2638: Consolidated Security, Disaster Assistance, and Continuing Appropriations Act for 2009
H.R. 7110/S.3604: Second Supplemental Appropriations Act for FY 2008
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Taylor |
|
|
|
Sandra |
Dennis |
|
|
|
Lauren |
Neff |
|
Leg. Assistant, Congresswoman Deborah Pryce |
|
Laurel |
Todd |
|
|
|
Sara |
Radcliffe |
|
|
|
Eli |
Joseph |
|
|
|
Melissa |
Bowie |
|
Chief Health Counsel, Senate HELP, Subcommittee |
|
Andrew |
Emmett |
|
|
|
Edward |
Buckley |
|
|
|
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
|
Tom |
DiLenge |
|
|
|
Jeanne |
Haggerty |
|
Policy Advisor, Congressman Joe Barton |
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SCI
16. Specific lobbying issues
Stem Cell Research
Small Business Innovation and Research Program (SBIR)
H.R. 5819: SBIR Reauthorization Act
S.3362
SBA Proposed Rule on SBIR Award Caps
R&D Tax Credit
H.R. 6049
H.R. 1424
Election of R&D/AMT Tax Credits in Lieu of Bonus Depreciation
H.R. 3221
Technology Innovation Program (TIP)
Proposed Rules by National Institutes for Standards & Technology
Funding
S:3282: Commerce, Justice, Science, and Related Agencies Appropriations Act for FY 2009
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Treasury - Dept of, Commerce - Dept of (DOC), Natl Institute of Standards & Technology (NIST), Small Business Adminstration (SBA), Office of Science & Technology Policy (OSTP), Natl Institutes of Health (NIH), Natl Economic Council (NEC), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tricia |
Brooks |
|
|
|
Cartier |
Esham |
|
|
|
Alan |
Eisenberg |
|
|
|
Paul |
Poteet |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Eli |
Joseph |
|
|
|
Tooshar |
Swain |
|
Legislative Correspondent, Senator Rick Santorum |
|
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
|
Melissa |
Bowie |
|
Chief Health Counsel, Senate HELP, Subcommittee |
|
Tom |
DiLenge |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Small Business Innovation and Research Program (SBIR)
H.R. 5819: SBIR Reauthorization Act
S.3362
SBA Proposed Rule on SBIR Award Caps
Sarbanes-Oxley Reform
Section 404
S.3260: Financial Services and General Government Appropriations Act for FY 2009
FDA Regulatory Processes for First-Time Filers
Election of R&D/AMT Tax Credits in Lieu of Bonus Depreciation
H.R. 3221
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Small Business Adminstration (SBA), Treasury - Dept of, Food & Drug Administration (FDA), Natl Economic Council (NEC), Office of Science & Technology Policy (OSTP), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Melissa |
Bowie |
|
Chief Health Counsel, Senate HELP, Subcommittee |
|
Cartier |
Esham |
|
|
|
Alan |
Eisenberg |
|
|
|
Eli |
Joseph |
|
|
|
Paul |
Poteet |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Tooshar |
Swain |
|
Legislative Correspondent, Senator Rick Santorum |
|
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
|
Tom |
DiLenge |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Biofuels Tax Credit
R&D Tax Credit
H.R. 6049
H.R. 1424
Election of R&D/AMT Tax Credits in Lieu of Bonus Depreciation
H.R. 3221
Comprehensive Biotechnology Tax Incentives Legislation
H.R. 3264
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Treasury - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brent |
Erickson |
|
|
|
Matt |
Carr |
|
|
|
Amy |
Ehlers |
|
|
|
Paul |
Poteet |
|
|
|
Eli |
Joseph |
|
|
|
Tooshar |
Swain |
|
Legislative Correspondent, Senator Rick Santorum |
|
Shelly |
Mui-Lipnik |
|
|
|
Alan |
Eisenberg |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Cartagena Biosafety Protocol
U.S. Government Positions/Activities/Communications at Biosafety Protocol Meetings
Foreign Agricultural Biotechnology Laws and Regulations
U.S. Korea Free Trade Agreement
China Biotechnology Trade Negotiations
Mexico Biotechnology Trade Negotiations
Vietnam Biotechnology Negotiations
France Trade Meetings
Taiwan Biotechnology Negotiations
EU Trade Negotiations
Korea Biotechnology Trade Negotiations
Canada Biotechnology Trade Negotiations
Japan Biotechnology Trade Negotiations
Peru Biotechnology Trade Negotiations
Argentina Biotechnology Trade negotiations
Adventitious Presence (Low Level Presence)
U.S. Government Policy Position for Codex Guidelines on Adventitious Presence
European Union Low Level Presence Policy
World Trade Organization on EU Biotech Approvals
Review of EU Biotechnology Negotiations
CBD TRIPS Amendment
Patent Disclosure Requirements
Intellectual Property and Access to Medicines for Neglected Diseases and Diseases of Developing World
U.S. Government Positions in WTO, WHO Negotiations
Policies Impacting Global Trade of Ag-Biotech Products
U.S. Government Positions
International Market Access for U.S. Healthcare Products
Alliance for Healthcare Competitiveness
Drug Importation
S: 3230: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY
2009
S.3181: Department of Homeland Security Appropriations Act for FY 2009
S: 3289: Departments of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies
Appropriations Act for FY 2009
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), Commerce - Dept of (DOC), Environmental Protection Agency (EPA), State - Dept of (DOS), U.S. Trade Representative (USTR), U.S. Agency for International Development (USAID), Health & Human Services - Dept of (HHS), White House Office, Patent & Trademark Office (PTO)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
|
John |
Taylor |
|
|
|
Sharon |
Bomer Lauritsen |
|
|
|
Sarah |
Lukie |
|
|
|
Eli |
Joseph |
|
|
|
Lila |
Feisee |
|
|
|
Paul |
Poteet |
|
|
|
Bill |
Olson |
|
Legislative Assistant, Rep. John Shimkus |
|
Tom |
DiLenge |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code GOV
16. Specific lobbying issues
False Claims Act Amendment
S.2041
H.R. 4854
.
Access to Drug Pricing Data
H.R. 5683
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Eli |
Joseph |
|
|
|
Melissa |
Bowie |
|
Chief Health Counsel, Senate, HELP, Subcommittee |
|
Jeanne |
Haggerty |
|
Policy Advisor, Congressman Joe Barton |
|
Tom |
DiLenge |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LAW
16. Specific lobbying issues
Human Growth Hormone Regulation
S.877
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Eli |
Joseph |
|
|
|
Sandra |
Dennis |
|
|
|
Jeanne |
Haggerty |
|
Policy Advisor, Congressman Joe Barton |
|
Melissa |
Bowie |
|
Chief Health Counsel, Senate HELP, Subcommittee |
|
Tom |
DiLenge |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address | |
||||||
| City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
| City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
5 |
|
||||||
| 2 |
|
6 |
|
||||||
| 3 |
|
7 |
|
||||||
| 4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
CIV |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address: BIO maintains a list of all of its members on its website at http://bio.org/membership/index.asp
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 3 | 5 |
| 2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 5 | 9 |
| 2 | 6 | 10 |
| 3 | 7 | 11 |
| 4 | 8 | 12 |